Collin J. LaCasse

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL− Tumors

Nicolas Larmonier, Nona Janikashvili, Collin J. LaCasse et al. · The Journal of Immunology · 2008 · 160 citations · Full text

Life Sciences, Immunology, Oncology +17

Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25−FoxP3− T cells

Sara Centuori, Malika Trad, Collin J. LaCasse et al. · Journal of Leukocyte Biology · 2012 · 80 citations · Full text

Medicine, Immunology, Oncology +17

Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism

Collin J. LaCasse, Nona Janikashvili, Claire B. Larmonier et al. · The Journal of Immunology · 2011 · 49 citations · Full text

Life Sciences, Immunology, Oncology +15

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia

Nona Janikashvili, Collin J. LaCasse, Claire B. Larmonier et al. · Blood · 2010 · 26 citations

Life Sciences, Immunology, Oncology +12

Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells

Jessica Cantrell, Claire B. Larmonier, Nona Janikashvili et al. · Immunobiology · 2009 · 11 citations

Medicine, Immunology, Oncology +14